Optimal measurable residual disease testing for acute myeloid leukemia Review

  


Authors: Xiao, W.; Petrova-Drus, K.; Roshal, M.
Review Title: Optimal measurable residual disease testing for acute myeloid leukemia
Abstract: Increasing evidence supports the prognostic significance of measurable residual disease (MRD) in acute myeloid leukemia (AML). Dynamic MRD assessment for patients with AML complements baseline patient risk assessment factors in determining patient prognosis. MRD status may also be helpful in informing therapeutic decisions. The European Leukemia Net MRD working party recently issued consensus recommendations for the use of MRD in AML. The Food and Drug Administration also issued advice for using MRD in trials of hematologic malignancies. This article discusses MRD testing, highlights the challenges in adopting MRD testing in clinical practice, and provides insights into the future of the field. © 2019 Elsevier Inc.
Keywords: flow cytometry; acute myeloid leukemia; next-generation sequencing; droplet digital pcr; minimal/measurable residual disease; molecular assays; rt-qpcr
Journal Title: Surgical Pathology Clinics
Volume: 12
Issue: 3
ISSN: 1875-9181
Publisher: Elsevier Inc.  
Date Published: 2019-09-01
Start Page: 671
End Page: 686
Language: English
DOI: 10.1016/j.path.2019.03.009
PROVIDER: scopus
PUBMED: 31352980
DOI/URL:

https://www.scopus.com/inward/record.uri?eid=2-s2.0-85065772282&doi=10.1016%2fj.path.2019.03.009&partnerID=40&md5=4926cec8ee742b7a00df2658ad91a94f
Notes: Source: Scopus
Altmetric
What is Altmetric?
Citation Impact
What is Dimensions Citation Badge?
BMJ Impact Analytics
MSK Authors
  1. Mikhail Roshal
    227 Roshal
  2. Wenbin Xiao
    108 Xiao
  3. Kseniya Petrova-Drus
    61 Petrova-Drus
Related MSK Work